Olumiant (baricitinib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Olumiant (baricitinib)

How to buy Olumiant: You can order Olumiant (baricitinib) via TheSocialMedwork if the drug has not been approved and/or is not approved in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Eli Lilly and Co.
Disease Rheumatoid Arthritis
Indication Moderate to severe rheumatoid arthritis
Mode of Action Inhibitor of Janus kinases (JAKs)
Approval Status EMA approved (EU)
Strength 2 mg

Who is baricitinib for?

Olumiant (baricitinib) is indicated for the treatment of patients with moderate to severe rheumatoid arthritis when standard treatment with disease-modifying anti-rheumatic drugs (also known as ‘DMARDs’) has not worked well enough, or if patients cannot tolerate them. Olumiant can be used either alone or in combination with the disease modifying drug, methotrexate [1].

Recommended dose

Complete information about Olumiant (baricitinib) dosage and administration can be found here: [2].
The standard dosage is:
  • 4 mg once a day
The dose can be reduced to 2 mg once a day when the disease is under control or under certain conditions like kidney function or age of the patient.
Consult your treating doctor for personalised dosing.

What is baricitinib and how does it work?

Olumiant (baricitinib) is an inhibitor of Janus kinases (JAKs) used to treat adult patients with moderate to severe rheumatoid arthritis when standard treatment with disease-modifying anti-rheumatic drugs (also known as ‘DMARDs’) has not worked well enough or if patients cannot tolerate them [1].
The active substance in Olumiant, baricitinib, works by blocking the action of enzymes known as Janus kinases which play an important role in the process of inflammation and joint damage that occurs in rheumatoid arthritis. By blocking their action, baricitinib helps reduce the inflammation and other symptoms of the disease [1].

What is baricitinib's approval status?

Olumiant, baricitinib, was approved by:
  • EMA (EU) on February 2, 2017 [1]
for patients with moderate to severe rheumatoid arthritis when standard treatment with disease-modifying anti-rheumatic drugs has not worked well enough or if patients cannot tolerate them.
The approval was based on four Phase III randomised, double-blind, multicentre studies in patients with moderate to severe active rheumatoid arthritis [2]. An important measure in patients with rheumatoid arthritis is the ACR 20, 50 or 70 which is a criteria to measure the improvement of patients of 20 %, 50 % or 70 % based on measures as swollen joint count, tender joint count, patient assessment of global status, acute phase reactant (dramatic increase in hepatic synthesis of plasma proteins which accompanies acute phases of tissue injury and inflammation), health professional assessment of global status, physical function, and pain [6].
In all studies, patients treated with 4 mg of Olumiant once daily had statistically significantly higher ACR20, ACR50 and ACR70 responses at 12 weeks compared to placebo, MTX or adalimumab. Time to onset of efficacy was rapid across measures with significantly greater responses seen as early as week 1. Continued, durable response rates were observed, with ACR20/50/70 responses maintained for at least 2 years [2].
From the study RA-BEAM it resulted that in patients previously treated with methotrexate, after 12 weeks 70 % of patients (339 out of 487) on Olumiant achieved at least a 20 % improvement in symptom scores (ACR20), compared with 61% of patients (202 out of 330) on adalimumab and 40 % (196 out of 488 patients) on placebo [1].
From the study RA-BUILD it resulted that in patients previously treated with conventional disease modifying drugs, 62 % of patients (140 out of 227) on baricitinib achieved at least a 20 % improvement, compared with 40 % of patients (90 out of 228) on placebo [1].
The study RA-BEACON focused on patients previously treated with a class of disease modifying drugs called TNF-inhibitors and, within this group, it compared the effect of baricitinib with placebo. It resulted after 12 weeks 55 % of patients (98 out of 177) on baricitinib achieved at least a 20 % improvement, compared with 27 % of patients (48 out of 176) on placebo [1].
The study RA-BEGIN focused on patients that had not been previously treated with methotrexate and, within this group, it compared the effect of baricitinib with placebo. It resulted that after 12 weeks 79 % of patients on baricitinib alone achieved at least a 20 % improvement, compared with 77 % of patients on baricitinib and methotrexate, and 56 % of patients on methotrexate alone [2].
The most common side effects with baricitinib used alone or in combination with methotrexate were increased blood cholesterol levels, nose and throat infections, and nausea [1].
[1] EMA. Human medicines: Olumiant (baricitinib), 16/03/2017, cited on 20/06/2017
[2] Summary of Product Characteristics [EMA]: Olumiant (baricitinib), Eli Lilly Nederland B.V., Mar. 2015.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.